Martin (Marty) Moore (BS ’95, PHD ‘03) is co-founder and CEO of Meissa Vaccines, a private, clinical-stage, venture-backed biotech company focused on the advancement of vaccines for respiratory viruses.
Meissa was founded in an effort to develop a pediatric vaccine for respiratory syncytial virus (RSV). Prior to cofounding Meissa, Marty was an Associate Professor at Emory University and director of the Emory Children’s Center for Childhood Infections and Vaccines (CCIV), where he led the development of the RSV vaccine using a synthetic biology technology that was recognized as Emory University’s innovation of the year in 2013.
Meissa recently launched clinical trials and established a COVID-19 vaccine program to combat the ongoing pandemic. Meissa’s COVID-19 vaccine candidate is designed for needle-free intranasal administration and global distribution.
Dr. Moore and cofounder Roderick Tang recruited a team of virologists and vaccinologists with collectively more than 200 years of experience in vaccine development.
Marty signed an Innovators’ Pledge in 2021.
Meet other Innovators and learn about the Innovators’ Pledge.